November 11, 2021
1 min read

‘Six months after second dose ideal time for booster’

At the Times Now Summit 2021, Ella also opened up about the hurdles faced in Covaxin’s WHO approval…reports Asian Lite News.

Hyderabad-based pharma major Bharat Biotech founder and Managing Director Dr Krishna Ella on Wednesday said that an ideal time for booster dose of a coronavirus vaccine would be six months after receiving the second dose.

However, he added that a final decision will be taken by the government.

About the nasal vaccine being developed by Bharat Biotech after its Coavaxin, he said that the Phase 2 trials are done and data was being analysed. “We should expect it in 3-4 months,” he said, adding that Bharat Biotech was also talking to the government about using the Cowin platform for doing clinical trials.

Ella indicated that the nasal Covid vaccine could be taken instead of the second dose of Covaxin or to protect previously infected persons. The nasal vaccine was more effective in preventing infection as compared to an injectable vaccine which does not reach upper lungs and could eliminate the need for a vaccinated individual to continue wearing the mask, he said.

On bringing a vaccine for children, Ella said Bharat Biotech was the only company in the world to have done clinical trials among those between 2 and 18 years of age.

At the Times Now Summit 2021, Ella also opened up about the hurdles faced in Covaxin’s WHO approval.

He said that they had 5 vaccines WHO pre-qualified “so we knew it very well, we know how to do it. But the problem is many media people who are negative, they even wrote to the scientific journals to look into some death in Bhopal. It happened because of suicide but it was blamed on vaccine”.

Asked about the reason behind the negative publicity, the Bharat Biotech founder responded: “When Prime Minister took the vaccine, immediately they said it’s a BJP vaccine, it’s a Modi vaccine. All sorts of synonyms. We are scientists, we don’t understand the politics.”

The World Health Organisation granted emergency use listing to India’s indigenous vaccine Covaxin on November 3.

ALSO READ-Pfizer seeks FDA nod for Covid booster jab in US

Previous Story

Congress to take out 403 yatras in UP

Next Story

Giant Syrian refugee girl puppet symbol of hope at COP26

Previous Story

Congress to take out 403 yatras in UP

Next Story

Giant Syrian refugee girl puppet symbol of hope at COP26

Latest from -Top News

Nepal Seeks $2bn Lifeline From India

Nepal to seek over $2 billion in Indian aid during PM Shah’s visit…reports Asian Lite News Desk Nepal is preparing to seek more than $2 billion in financial assistance from India during

UN Unveils $18m Winter Aid For Afghanistan

UN approves $18 million emergency aid for 824,000 people in Afghanistan…reports Asian Lite News Desk The United Nations has approved $18 million in emergency humanitarian funding to support approximately 824,000 people in

COP31 Taskforce Targets Ocean Climate Funding Gap

France and Brazil have launched a 25-country initiative at COP31 to accelerate ocean-based climate solutions, as new data highlights major funding gaps threatening the implementation of national commitments…reports Asian Lite News Desk
Go toTop